reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00

Driving Business Advantage

regulatory summary of 105 Cmr 970.000

final Pharmaceutical and medical Device manufacturer Conduct regulations

march 2009

by Pat a. Cerundolo, Colin J. Zick & tad Heuer

on march 11, 2009, the massachusetts Public Health Council promulgated final regulations (105 Cmr 970.000) for the administration of Chapter 111N of the massachusetts general laws, which governs the marketing activities of pharmaceutical and medical device manufacturing companies. When the legislature passed Chapter 111N in august 2008 (as section 14 of Chapter 305 of the acts of 2008) (the “law”), massachusetts joined the District of Columbia and six other states in regulating the relationships between the pharmaceutical and medical device industries and physicians.

understanding these final regulations is of significant importance to anyone involved in the massachusetts biotechnology, health care, and drug and device sectors. the regulations apply broadly to pharmaceutical or medical device manufacturing companies (“PmDmCs”), including companies that are “directly” engaged in the packaging, repackaging, labeling, relabeling or distribution of prescription drugs, biologics or medical devices. In accordance with the requirements of the law, the regulations establish a fine of $5,000 for each knowing and willful violation.

as summarized in greater detail below, the final regulations generally track the substance and organization of the law, in three key areas:

• First,theregulationsestablishamarketingcodeofconductthat applies to both pharmaceutical and medical device companies, with certain limited exceptions.

I. Overview of the Final Regulations

1

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 • Second,theregulationsmandatethatPMDMCsimplement

certain training and compliance programs, and provide related certifications to the Department of Public Health (“DPH”).

• Third,theregulationsrequirePMDMCstodisclosecertain payments and other benefits provided to certain covered recipients, and clarify that these disclosures are limited to sales and marketing activities. the disclosures will be made publicly available for review on a dedicated website.

II. Summary of the Final Regulations A. Section 970.005: General Requirements

Adoption of Marketing Code of Conduct and Training Programs

• RequiresthatbyJuly1,2009,eachPMDMCthat“employsor contracts with a pharmaceutical or medical device manufacturer agent” must (a) adopt a code of conduct consistent with the regulations, (b) adopt and submit to DPH a description of a training program for the code, (c) certify compliance with the code “to the best of the company’s knowledge”, (d) adopt and submit to DPH a program for addressing non-compliance, and (e) identify a compliance officer.

Non-patient Prescriber Data

• Requirespharmaceuticalmanufacturersusingnon-patient identified prescriber data to (a) maintain confidentiality, (b) develop policies regarding use of the data and educate employees about such policies, (c) designate an internal contact person for data inquiries, (d) establish appropriate disciplinary

2

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

actions for data misuse, (e) withhold the data from sales representatives at the request of health care practitioners (“HCPs”), and (f) give HCPs the opportunity to request that their prescriber data be withheld from company representatives and not be used for marketing purposes.

• AllowsPMDMCstouseprescriberdatatoimpartimportantsafety and risk information to prescribers, conduct research, comply with fDa-mandated risk management plans, or track adverse effects of drugs or devices.

Disclosures to Formulary and Clinical Guidelines Committees

• RequiresPMDMCstorequireanyHCPwhoboth(a)servesasa member of a committee that sets formularies or develops clinical guidelines, and (b) serves as a speaker or commercial consultant for the PmDmC, to disclose to the committee the nature and existence of his or her PmDmC relationship.

Annual Audits

• RequireseachPMDMCtocertifyannuallytoDPHthatithas conducted an internal annual audit in compliance with the code. the first certification is required on July 1, 2010.

B. Section 970.006: Provision of Meals

Prohibitions on Certain Meals

• ProhibitsPMDMCsthatemployorcontractwithpharmaceutical or medical device agents from providing or paying for meals that are (a) part of an entertainment or recreational event, (b) offered without an informational presentation, (c) provided to a spouse or other guest, or (d) offered outside the “office or hospital setting,” where that term is defined as a hospital, an academic medical

3

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 center, or a facility that the PmDmC has certified to DPH as being a

“specialized training facility.”

C. Section 970.007: CME, Third-party Scientific or Educational Conferences, or Professional Meetings (“Events”)

Prohibitions on Funding for Certain Events

• ProhibitsPMDMCsthatemploypharmaceuticalormedicaldevice manufacturer agents from:

• directlyorindirectlyreimbursingtheexpensesof“non-faculty” physicians attending events,

• compensatingphysiciansfortimespentattendingEvents,

• payingformealsdirectlytoHCPsatEvents(althoughaCME provider or conference organizer may use PmDmC funding to provide meals for all participants), or

• sponsoringCMEEventsnotmeetingACCMEorequivalent standards.

Reasonable Faculty Compensation

• Permits“reasonable”and“fairmarketvalue”compensationor expense reimbursement to HCPs serving as speakers, faculty organizers, or academic program consultants for an event.

Separation of CME Funding

• RequirespharmaceuticalmanufacturerstoseparatetheirCME grant-making functions from their sales and marketing departments, and prohibits pharmaceutical manufacturers from providing advice or guidance to a Cme provider regarding the content or faculty for a Cme program funded by the company.

4

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

Facilities

• Permitstheuseofhotelorconventioncenterfacilitiesorother venues for events.

D. Section 970.008: Other Miscellaneous Payments

Allowable Payments

• AllowscertainPMDMCpaymentactivities,including:

• reasonablecompensationorexpensereimbursementsfor “bona fide services,” (defined as including research, participation on advisory boards, collaboration with nonprofits dedicated to the promotion of health and the prevention of disease, and presentations at company-sponsored medical education and training as formalized in a written agreement),

• distributionofpeerreviewedacademic,scientificorclinical information, and the purchase of advertising in academic, scientific, or clinical journals,

• freesamplesofprescriptiondrugsforusebypatients,

• paymentfordevicetrainingexpensespursuanttoa written agreement,

• freemedicaldevicedemonstrationandevaluationunitsfor evaluation purposes,

• priceconcessions,rebatesordiscountsinthenormalcourse of business,

• reimbursementinformationconcerningproductsthatsupport accurate billing to medicare and other payors, so long as the information is not offered to induce physicians to purchase,

5

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 lease, or use products,

• payments,orfreeoutpatientprescriptiondrugs,provided through certain established patient assistance programs, and

• certaincharitabledonations.

Prohibited Payments

• ProhibitscertainPMDMCpaymentactivity,including:

• theprovisionofentertainmentorrecreationalitemstoHCPs that are not salaried employees of the PmDmC,

• paymentsofanykind,includingcash,equity,“inkind” payments, and “complimentary items” such as pens and mugs, except as compensation for bona fide services,

• grantsorscholarships,consultingcontracts,educationalor practice items provided in exchange for prescribing or using drugs or devices, and

• anyotherpaymentorremuneration,includinganyrebateor “kickback” that is prohibited under federal or state fraud and abuse laws.

E. Section 970.009: Disclosure of Payments

De Minimis Exception

• RequiresPMDMCsthatemploymarketerstodisclose“thevalue, nature, purpose and particular recipient of any fee, payment, subsidy or other economic benefit with a value of at least $50, which the company provides, directly or through its agents, to any covered recipient in connection with the company’s sales and marketing activities.”

6

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

• Clarifiesthatforthepurposesofcomputingthe$50threshold, “fees, payments, subsidies and other economic benefits relating to separate events or transactions shall be calculated on an individual transactional basis and shall not be aggregated.”

Definition of “Sales and Marketing Activities”

• Forthepurposesofthedisclosurerequirement,“salesand marketing activities” include:

• advertising,promotionorotheractivitythatisintendedtobe used or is used to (a) influence the sale or the market share of a prescription drug, biologic or medical device, or the prescribing behavior of a covered recipient, (b) to market a drug or device, or (c) to evaluate the effectiveness of a pharmaceutical or medical device detailing sales force.

• anyproducteducation,training,orresearchprojectthatis designed or sponsored by the marketing division of a PmDmC, or has marketing, product promotion, or advertising as its purpose.

Activities Exempt from Disclosure

• Thefollowingarenot“salesandmarketingactivities”for purposes of the disclosure requirement, and are thus exempt from disclosure:

• clinicaltrialsand“genuineresearch”,particularlywherethe primary purpose is “to generate data in support of an application filed with the fDa seeking approval for a new drug, biologic or medical device or ‘new use’ or similar marketing or labeling claim requiring fDa approval.” (“genuine research” is defined as a project “intended to add to medical knowledge about the care and treatment of patients that constitutes a systematic investigation, designed to develop or contribute to

7

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 generalizable knowledge when the results can be published by

the investigator and reasonably can be considered to be of significant interest or value to scientists or health care practitioners working in the particular field of inquiry”),

• clinicaltrialspostedonwww.clinicaltrials.gov

• theprovisionofprescriptiondrugsforusebypatients,

• theprovisionofdemonstrationorevaluationunits,

• in-kinditemsusedfortheprovisionofcharitycare,and

• confidentialpriceconcessions“establishedincontracts between pharmaceutical or medical device manufacturing companies and insurers, pharmacies, pharmacy benefit managers or health plan administrators and their affiliates that are offered in connection with the acquisition of drugs, biologics or medical devices or the management of a health plan’s formulary.”

Required Certification and Fees

• RequiresPMDMCstocertifytheirdisclosurereportsastrueand accurate, and to submit with each annual report a $2,000 fee. the first fee is due on July 1, 2009, even though the first report is not due until July 1, 2010.

Reporting Deadlines

• RequiresthatdisclosurereportsbefiledbyJuly1,2010for payments occurring from July 1, 2009 through December 31, 2009, and annually thereafter (by July 1) for payments occurring during the previous calendar year.

8

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

F. Section 970.010: Penalties

Monetary Fines

• Establishesafineofnotmorethan$5,000foreachknowingand willful violation of the regulations.

Whistleblower Protections

• Establisheswhistleblowerprotectionsforindividualswhotake actions in furtherance of the regulations.

III. Comprehensiveness

DPH has stated that these regulations are the most comprehensive of their kind in the nation. Particularly, DPH has noted that, with the adoption of the regulations, massachusetts is the only state to (a) require adoption of and compliance with a state-authored marketing code of conduct, (b) prohibit certain payments to physicians by both pharmaceutical and medical device manufacturers, and (c) require disclosures by medical device manufacturers. the regulations also make massachusetts one of two states that make disclosure data part of the public record.

9

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 105 Cmr 970.000: Pharmaceutical and

medical Device manufacturer Conduct970.001: Purpose

105 Cmr 970.000 is set forth to implement m.g.l. c. 111N, Pharmaceutical and medical Device manufacturer Conduct, as enacted under Chapter 305 of the acts of 2008, an act to Promote Cost Containment, transparency and efficiency in the Delivery of Quality Health Care. 105 Cmr 970.000 is intended to benefit patients, enhance the practice of medicine, and ensure that the relationship between pharmaceutical or medical device manufacturers and health care practitioners not interfere with the independent judgment of health care practitioners. Pursuant to m.g.l. c. 111N, the regulation seeks to accomplish these objectives without compromising companies’ legitimate confidentiality interests in protecting trade secrets and other intellectual property rights associated with genuine medical research, clinical trials, and the discovery of new treatments and medical devices.

970.002: Regulatory Authority

105 Cmr 970.000 is adopted under the authority of m.g.l. c.111, s.3 and m.g.l. c.111N.

970.003: Citation

105 Cmr 970.000 shall be known, and may be cited, as the Pharmaceutical and medical Device manufacturer Code of Conduct or the marketing Code of Conduct.

970.004: Definitions

the following terms as used in 105 Cmr 970.000 shall have the

10

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

following meanings, unless the context or subject matter clearly require a different interpretation:

“authorized entity,” the attorney general, the district attorney with jurisdiction over a violation, or the department of public health.

“Biologic,” a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, immunoglobulin product, or analogous product, as defined by section 351 of the Public Health service act applicable to the prevention, treatment, or cure of a disease or condition of human beings and regulated as a drug under the federal food, Drug, and Cosmetic act.

“Bona fide services,” an arrangement for services including, but not limited to, research, participation on advisory boards, collaboration with 501(c)(3) organizations dedicated to the promotion of health and the prevention of disease, and presentations at pharmaceutical or medical device manufacturing company-sponsored medical education and training including u.s. food and Drug administration (“fDa”) required education and training involved in producing safe and effective medical devices, provided such an arrangement is formalized in a written agreement specifying the services to be provided, based on the fair market value of the services and characterized by the following factors:

• alegitimateneedfortheservicesclearlyidentifiedinadvance;

• aconnectionbetweenthecompetenceandexpertiseofthe healthcarepractitionerandthepurposeofthearrangement;

• thenumberofhealthcarepractitionersretainedisnotgreater than the number reasonably necessary to achieve the identified purpose;

• theretainingpharmaceuticalormedicaldevicemanufacturing company maintains records concerning the arrangement and

11

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 makes appropriate use of the services provided by the health

carepractitioner;

• thevenueandcircumstancesofanymeetingwiththehealthcare practitioner is conducive to the services and activities related to theservicesaretheprimaryfocusofthemeeting;and

• thedecisiontoretainahealthcarepractitionerisnotunduly influenced by a pharmaceutical or medical device manufacturing company’s sales personnel.

“Charitable donation,” the provision of financial support to a 501(c)(3) or the in-kind provision of drugs, biologics or medical devices for charity care of patients.

“Clinical trial,” a genuine research project involving a drug or medical device that evaluates the safety or effectiveness of the particular drug, biologic or medical device in the screening, prevention, diagnosis, evaluation or treatment of a disease or health condition, or evaluates the safety or efficacy of the drug or medical device in comparison with other therapies, and which has been approved by the fDa and, if the trial involves volunteer human research subjects, it has been approved by a duly constituted Institutional review Board (“IrB”) after reviewing and evaluating it in accordance with the human subject protection standards set forth at 21 C.f.r. Part 50, 45 C.f.r. Part 46, or equivalent standards of another federal agency.

“Covered recipient,” a person authorized to prescribe, dispense, or purchase prescription drugs or medical devices in the commonwealth, including a hospital, nursing home, pharmacist, health benefit plan administrator, or a health care practitioner. a person who otherwise meets this definition but is a bona fide employee of a pharmaceutical or medical device manufacturing company shall not be a covered recipient. additionally, consumers

12

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

who purchase prescription drugs or medical devices are not covered recipients.

“Conference or meeting,” any convening where responsibility for and control over the selection of content, faculty, educational methods, materials, and venue belongs to the event’s organizers in accordance with their guidelines, held in a venue that is appropriate and conducive to informational communication and training about medical information, where (a) the gathering is primarily dedicated, in both time and effort, to promoting objective scientific and educational activities and discourse (one or more educational presentation(s) should be the highlight of the gathering), and (b) the main purpose for bringing attendees together is to further their knowledge on the topic(s) being presented.

“Department,” the department of public health.

“genuine research Project,” a project intended to add to medical knowledge about the care and treatment of patients that constitutes a systematic investigation, designed to develop or contribute to generalizable knowledge when the results can be published by the investigator and reasonably can be considered to be of significant interest or value to scientists or health care practitioners working in the particular field of inquiry.

“Health care practitioner”, a person who prescribes prescription drugs for any person and is licensed to provide health care in the commonwealth, or a partnership or corporation comprised of such persons, or an officer, employee, agent or contractor of such person acting in the course and scope of his employment, agency or contract related to or in support of the provision of health care to individuals. Hospitals are not healthcare practitioners. additionally, full time employees and board members of pharmaceutical or medical device manufacturers are not health care practitioners.

13

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 “Hospital setting,” (a) a hospital (b) academic medical center or (c)

pharmaceutical or medical device specialized training facility, where the facility, as certified to the Department by the pharmaceutical or medical device manufacturing company, is specifically designed to approximate the conditions of a surgical suite, or the conditions of a working clinical laboratory or to provide medical training on large and/or technical medical devices, such as surgical equipment, implants, and imaging and clinical laboratory equipment.

“medical device,” an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related article, including any component, part or accessory, which is: (1) recognized in the official National formulary or the united states Pharmacopeiaoranysupplementthereto;(2)intendedforuseinthediagnosis of disease or other conditions or in the cure, mitigation, treatmentorpreventionofdisease,inpersonsoranimals;or(3)intended to affect the structure or function of the body of a person or animal, and which does not achieve its primary intended purposes through chemical action within or on such body and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

“Non-faculty,” a health care practitioner who does not serve as a speaker or provide actual and substantive services as a faculty organizer or academic program consultant for a continuing medical education (“Cme”) event, third-party scientific or educational conference, or professional meeting.

“Person,” a business, individual, corporation, union, association, firm, partnership, committee or other organization.

“Pharmaceutical or medical device manufacturer agent,” a person who, while employed by or under contract with a pharmaceutical or

14

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

medical device manufacturing company, engages in detailing, promotional activities or other marketing of prescription drugs, biologics, or medical devices in the commonwealth to any physician, hospital, nursing home, pharmacist, health benefits plan administrator, other health care practitioner or person authorized to prescribe, dispense or purchase prescription drugs, biologics or medicaldevices;provided,however,that“pharmaceuticalormedicaldevice manufacturer agent” shall not include a licensed pharmacist, licensed physician or any other licensed health care practitioner with authority to prescribe prescription drugs, biologics or medical devices who is acting within the ordinary scope of the practice for which he or she is licensed, a wholesale drug distributor licensed under section 36a of chapter 112, a representative of such a distributor who promotes or otherwise markets the services of the wholesale drug distributor in connection with a prescription drug or a retail pharmacist registered under section 37 of said chapter 112 if such person is not engaging in such practices under contract with a manufacturing company.

“Pharmaceutical or medical device manufacturing company,” any entity that:

(a) is engaged in the production, preparation, propagation, compounding, conversion or processing of prescription drugs, biologics, or medical devices, either directly or indirectly, by extraction from substances of natural origin, or independently by means of chemical synthesis or by a combination of extraction andchemicalsynthesis;or

(b) is directly engaged in the packaging, repackaging, labeling, relabeling or distribution of prescription drugs, biologics, or medicaldevices;provided,however,that“pharmaceuticalor medical device manufacturing company” shall not include a health care practitioner, physician practice, home health agency, hospital licensed under m.g.l. c. 111, s. 51, a wholesale drug

15

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 distributor licensed under m.g.l. c. 112, s. 36a or a retail

pharmacist registered under m.g.l. c. 112, s. 37-39C.

“Prescription drugs,” drugs upon which the manufacturer or distributor has placed or is required by federal law and regulations to place the following or a comparable warning: “Caution federal law prohibits dispensing without prescription.”

“sales and marketing activities,” for the purposes of disclosure under 105 Cmr 970.009, sales and marketing activities include advertising, promotion, or other activity that is intended to be used or is used to influence sales or the market share of a prescription drug,biologicormedicaldevice;toinfluenceorevaluatetheprescribing behavior of a covered recipient to promote a prescription drug,biologic,ormedicaldevice;tomarketaprescriptiondrug,biologic,ormedicaldevice;ortoevaluatetheeffectivenessofaprofessional pharmaceutical or medical device detailing sales force. sales and marketing activities also include any product education, training, or research project that is designed or sponsored by the marketing division of a pharmaceutical or medical device manufacturing company or has marketing, product promotion, or advertising as its purpose.

sales and marketing activities also include the provision of any fee, payment, subsidy or other economic benefit with a value of at least $50 to a covered recipient except as follows: sales and marketing activities do not include clinical trials and genuine research, particularly where the primary purpose is to generate data in support of an application filed with the fDa seeking approval for a new drug, biologic or medical device or “new use” or similar marketing or labeling claim requiring fDa approval. Clinical trials that are posted on clinicaltrials.gov will be deemed exempt from disclosure. sales and marketing activities also shall not include the provision of

16

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

prescription drugs to a covered recipient solely and exclusively for use by patients, demonstration or evaluation units, in-kind items used for the provision of charity care, or confidential price concessions established in contracts between pharmaceutical or medical device manufacturing companies and insurers, pharmacies, pharmacy benefit managers or health plan administrators and their affiliates that are offered in connection with the acquisition of drugs, biologics or medical devices or the management of a health plan’s formulary.

970.005: General Requirements

1. By July 1, 2009, each pharmaceutical or medical device manufacturing company that employs or contracts with a pharmaceutical or medical device manufacturer agent shall:

a. adopt a marketing code of conduct in compliance with the requirements of 105 C.m.r. 970.000.

b. adopt and submit to the Department a description of a training program to provide regular training to appropriate employees including, without limitation, all sales and marketing staff, on the marketing code of conduct. the training program must:

i. ensure that all representatives who are employed by or acting on behalf of the company and who visit health care practitioners have sufficient knowledge of:

1. the marketing code of conduct,

2. general science, and

3. product-specific information to provide accurate, up-to- date information, consistent with state law and fDa requirements;and

ii. provide for regular assessments of persons who are employed by or acting on behalf of the companies to

17

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 ensure that they comply with the requirements of 105

C.m.r 970.000 and other relevant company policies.

c. certify to the Department to the best of the company’s knowledge, information and belief that it is in compliance with 105C.M.R.970.000;

d. adopt and submit to the Department policies and procedures for investigating non-compliance with 105 C.m.r. 970.000, taking corrective action in response to non-compliance and reporting instances of non-compliance to the appropriate state authorities;and

e. submit to the Department the name, title, address, telephone number and electronic mail address of the compliance officer it has identified as responsible for certifying compliance with 105 C.m.r. 970.000 and implementing, monitoring, and enforcing the company’s marketing code of conduct.

2. each pharmaceutical manufacturing company that uses non-patient identified prescriber data to facilitate communications with health care practitioners shall:

a.maintaintheconfidentialnatureofprescriberdata;

b. developpoliciesregardingtheuseofthedata;

c. educateemployeesandagentsaboutthesepolicies;

d. designate an internal contact person to handle inquiries regardingtheuseofthedata;

e. identify appropriate disciplinary actions for misuse of the data;and

18

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

f. comply with the request of any health care practitioner not to make his or her prescriber data available to company sales representatives.

g. Before utilizing health care practitioner prescriber data for marketing purposes, manufacturers must give health care practitioners the opportunity to request that their prescriber data :

i. be withheld from company sales representatives, and

ii. not be used for marketing purposes.

h. Nothing in this section shall prohibit pharmaceutical manufacturing companies from using prescriber data to:

i. impart important safety and risk information to prescribersofaparticulardrugordevice;

ii. conductresearch;

iii. comply with fDa mandated risk management plans that require manufacturers to identify and interact with health carepractitionerswhoprescribecertaindrugsordevices; or

iv. track adverse events of marketed drugs, biologics or devices.

3. In all speaker and commercial consultant contracts, pharmaceutical manufacturing companies shall require any health care practitioner who is a member of a committee that sets formularies or develops clinical guidelines and also serves as a speaker or commercial consultant for the company to disclose to the committee the nature and existence of his or her relationship with the company. this disclosure requirement must extend for at

19

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 least two years beyond the termination of any speaker or consultant

arrangement.

4. Beginning on July 1, 2010, and annually on or before July 1 of each year thereafter, each pharmaceutical and medical device manufacturing company must certify to the Department that it has conducted annual audits to monitor compliance with 105 C.m.r. 970.000.

970.006: Provision of Meals

1. except as otherwise provided in 105 Cmr 970.000, no pharmaceutical or medical device manufacturing company that employs or contracts with a pharmaceutical or medical device manufacturer agent may provide or pay for meals for health care practitioners that:

a. arepartofanentertainmentorrecreationalevent;

b. are offered without an informational presentation made by a pharmaceutical or medical device marketing agent or without suchanagentbeingpresent;

c. are offered, consumed, or provided outside of the health carepractitioner’sofficeorahospitalsetting;or

d. are provided to a healthcare practitioner’s spouse or other guest.

2. meals provided to health care practitioners in compliance with 105 Cmr 970.006 must be modest and occasional in nature.

20

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

970.007: CME, Third-Party Scientific or Educational Conferences, or Professional Meetings

1. No pharmaceutical or medical device manufacturing company that employs or contracts with a pharmaceutical or medical device manufacturer agent may provide:

a. financial support for the costs of travel, lodging, or other personal expenses of non-faculty health care practitioners attending any Cme event, third-party scientific or educational conference, or professional meetings, either directly to the individuals participating in the event or indirectly to the event’s sponsor.

b. funding to compensate for the time spent by health care practitioners participating in any Cme event, third-party scientific or educational conferences, or professional meetings;

c. payment for meals directly to a health care practitioner at any Cme event, third-party scientific or educational conferences, or professional meetings, although a Cme provider or conference or meeting organizer may, at its own discretion, apply any financial support provided by a pharmaceutical or medical device manufacturing company for the event to providemealsforallparticipants;

d. sponsorship or payment for Cme, also known as independent medical education, that does not meet the standards for Commercial support as established by the accreditation Council for Continuing medical education (“aCCme”) or equivalent commercial support standards of the relevant continuing education accrediting body, or that provides payment directly to a health care practitioner.

21

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 2. a pharmaceutical manufacturing company shall separate its Cme

grant-making functions from its sales and marketing departments.

3. a pharmaceutical manufacturing company shall not provide any advice or guidance to the Cme provider regarding the content or faculty for a particular Cme program funded by the company.

4. Nothing in these regulations shall prohibit:

a. compensation or reimbursement made to a health care practitioner serving as a speaker or providing actual and substantive services as a faculty organizer or academic program consultant for a Cme event, third-party scientific or educational conference, or professional meeting, provided that the payment:

1. isreasonable;

2. isbasedonfairmarketvalue;and

3. complies with the standards for commercial support as established by the relevant accreditation entity.

b. sponsorship or payment for any portion of a third-party scientific or educational conference, charitable conference or meeting, or professional meeting, where the payment is made directly to the conference or meeting organizers.

c. the use of hotel facilities, convention center facilities or other special event venues for Cme or other third-party scientific, educational or professional meetings or conferences.

22

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

970.008: Other Payments to Health Care Practitioners

1. No pharmaceutical or medical device manufacturing company that employs or contracts with a pharmaceutical or medical device manufacturer agent may provide:

a. entertainment or recreational items of any value, including, but not limited to, tickets to the theater or sporting events, concerts, sporting equipment, or leisure or vacation trips, to any health care practitioner who is not a salaried employee of thepharmaceuticalormedicaldevicemanufacturingcompany;

b. payments of any kind including cash or cash equivalents, equity, “in-kind” or tangible items including any “complimentary” items such as pens, coffee mugs, gift cards, etc. to health care practitioners either directly or indirectly, exceptascompensationforbonafideservices;

c. any grants, scholarships, subsidies, supports, consulting contracts, or educational or practice related items in exchange for prescribing, disbursing, or using prescription drugs, biologics or medical devices or for a commitment to continue prescribing, disbursing, or using prescription drugs, biologicsormedicaldevices;

d. any other payment or remuneration, in cash or in-kind, directly or indirectly, including any rebate or “kickback” that is prohibited under applicable federal or state “fraud and abuse” laws or regulations including the federal “anti-Kickback statute” (42 u.s.C. 1320a-7b) and equivalent massachusetts laws such as m.g.l. c. 118e, s. 41 and m.g.l. c. 175H, s. 3.

2. Nothing in these regulations shall prohibit the following:

a. reasonable compensation for bona fide services, or the reimbursement of other reasonable out-of-pocket costs incurred by the health care practitioner directly as a result of

23

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 the performance of such services, where the compensation

and reimbursement is specified in, and paid for under, a writtenagreement;

b. Payment or reimbursement for the reasonable expenses, including travel and lodging related expenses necessary for technical training of health care practitioners on the use of a medical device if the commitment to provide such expenses, and the amounts or categories of reasonable expenses to be paid, are described in the written agreement between the health care practitioner and the device vendor for the purchaseofthedevice;

c. the provision, distribution, dissemination or receipt of peer reviewedacademic,scientificorclinicalinformation;

d. the purchase of advertising in peer reviewed academic, scientificorclinicaljournals;

e. the provision of prescription drugs to a health care practitioner solely and exclusively for use by the health care practitioner’spatients;

f. the provision of reasonable quantities of medical device demonstration and evaluation units provided to a health care practitioner to assess the appropriate use and functionality of the product and determine whether or not and when to use or recommend the product in the future.

g. the provision of price concessions, such as rebates or discounts,inthenormalcourseofbusiness;

h. Provision of reimbursement information regarding products, including identifying appropriate coverage, coding, or billing of

24

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

products, or of procedures using those products and information, in support of accurate and responsible billing to medicare and other payors and provision of information designed to offer technical or other support intended to aid in the appropriate and efficient use or installation of products, provided, however, that this technical or other support shall not be offered or provided for the purpose of inducing health care practitioners to purchase, lease, recommend, use, or arrangeforthepurchase,leaseorprescriptionofproducts;or

i. the provision of payments, or the provision of free outpatient prescription drugs, to health care practitioners for the benefit of low income individuals, through established “patient assistance programs” (“PaPs”), provided the program meets the criterion for a permissible program in accordance with the relevant published guidance available from the u.s. Department of Health and Human services office of the Inspector general, or is otherwise permitted under applicable federal laws and regulations including the “anti-Kickback statute” (42 usC 1320a-7b).

j. the provision of charitable donations provided that the donation:

1. is not provided in exchange for prescribing, disbursing or using prescription drugs, biologics or medical devices or for a commitment to continue prescribing, disbursing or using prescription drugs, biologics or medical devices, and

2. does not otherwise violate the provisions of 105 C.m.r. 970.000.

25

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 970.009: Disclosure of Payments

1. Beginning July 1, 2010, and annually on or before July 1 of each year thereafter, every pharmaceutical or medical device manufacturing company that employs or contracts with a pharmaceutical or medical device manufacturer agent shall disclose to the Department the value, nature, purpose and particular recipient of any fee, payment, subsidy or other economic benefit with a value of at least $50, which the company provides, directly or through its agents, to any covered recipient in connection with the company’s sales and marketing activities.

2. each annual disclosure report shall be accompanied by a fee of $2,000. the first annual payment of $2,000 shall be due to the Department on July 1, 2009.

3. Disclosures shall be made for the previous calendar year using a standardized reporting format developed by the Department. the first required disclosure report shall cover the period from July 1, 2009 through December 31, 2009. each annual disclosure report may be submitted to the Department electronically.

4. Pharmaceutical or medical device manufacturing companies shall certify that to the best of the company’s knowledge, information and belief, the report is true and accurate.

5. for the purposes of computing the $50 threshold, fees, payments, subsidies and other economic benefits relating to separate events or transactions shall be calculated on an individual transactional basis and shall not be aggregated. Pharmaceutical or medical device manufacturing companies shall not structure fees, payments, subsidies or other economic benefits to health care practitioners to circumvent the reporting requirements of m.g.l. c. 111N, §6 and 105 C.m.r. 970.009.

26

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

970.010: Penalties

1. a person who knowingly and willfully violates 105 Cmr 970.000 shall be punished by a fine of not more than $5,000 for each transaction, occurrence or event.

2. No pharmaceutical or medical device manufacturing company, shall discharge, refuse to hire, refuse to serve or in any manner retaliate or take any adverse action against any employee, applicant, health care practitioner or covered recipient because such employee, applicant, health care practitioner, or covered recipient takes or has taken any action in furtherance of the enforcement of 105 Cmr 970.000.

970.011: Enforcement

1. fines pursuant to 105 Cmr 970.000 shall be issued by an authorized entity.

2. ten days prior to the issuance of any fine pursuant to 105 C.m.r. 970.000, the authorized entity shall provide notice and an informal opportunity to dispute the issuance of the fine in person or by counsel or other representative as to the proposed action.

3. Notice shall be provided by mail, postage prepaid, to the person’s usual place of business or, if unavailable, to the person’s last known address.

4. a person aggrieved by the issuance of a fine by an authorized entity pursuant to 105 Cmr 970.000 may seek judicial review in the superior Court.

5. an authorized entity may file a civil complaint in superior Court following the failure of any person to pay a fine issued by the authorized entity.

27

reg

ula

tory

su

mm

ary

of

10

5 C

mr

97

0.0

00 About Foley Hoag LLP

foley Hoag llP is a leading national law firm in the areas of dispute resolution, intellectual property, and corporate transactions for emerging, middle-market, and large-cap companies. With a deep understanding of clients’ strategic priorities, operational imperatives, and marketplace realities, the firm helpscompanies in the biopharma, high technology, energy technology, financial services and manufacturing sectors gain competitive advantage. the firm’s 225 lawyers located in Boston, Washington, and the emerging enterprise Center in Waltham, massachusetts join with a network of lex mundi law firms to provide global support for clients’ largest challenges and opportunities. for more information visit foleyhoag.com.

Pat A. CerundoloPat Cerundolo’s highly diverse administrative law, litigation and regulatory practice involves representing both private and public sector clients in a variety of local, state and federal regulatory concerns. He has assisted business clients from the energy, biotechnology and transportation industries, and represents telecommunications clients in connection with the regulation of fiber optic and wireless networks, including regulatory compliance, open access issues, and permitting. His work for public entity clients encompasses zoning matters, eminent domain, land use and related litigation.

Click the image below for a full biography.

Pat A. Cerundolo

Colin J. ZickColin Zick’s practice is focused on health care and compliance issues, and often involves the intersection of those two subjects in administrative proceedings or litigation. His work has had a particular emphasis on compliance issues related to pharmaceutical and medical device companies, hospitals, practitioners (including physicians, dentists, optometrists, psychologists, veterinarians), and provider organizations. this compliance work includes helping clients establish and maintain effective compliance programs. Colin defends clients in disputes alleging kickbacks, overpayments, and billing and coding problems, and represents before various state health care licensing and regulatory entities.

Click the image below for a full biography.

Colin Zick

fINal P

Har

maC

eutIC

al aND

meD

ICal D

evICe m

aNu

faCtu

rer

Co

ND

uC

t reg

ulatIo

Ns

Tad Heuertad Heuer’s practice focuses on advising both private and public sector clients in two main areas: the development of government strategies at the federal, state, and local levels, and on matters pertaining to real estate, permitting, and land use development. In the field of government strategies, tad provides advice and guidance to a diverse array of clients -- including educational institutions and companies, life sciences companies, and health care providers -- on a wide range of federal, state, and local legislative and regulatory matters. tad brings to foley Hoag considerable experience in the government and nonprofit sectors, having worked previously for the u.s. Department of education, the New england Board of Higher education, the massachusetts Institute for a New Commonwealth (massINC), and several massachusetts state legislators. tad also holds a doctorate in social Policy & administration, with a focus on education regulation.

Click the image below for a full biography.

Tad Heuer

Foley Hoag eBook Library sample other free titles from the foley Hoag eBook library, sign-up for industry-specific alerts and updates from foley Hoag, or visit our Web site.

you may also be interested in our eBook series. simply click on an image to download or visit foleyhoag.com for our library.

sign up for industry-specific alerts and updatesvisit our Web site

Driving Business Advantage BostoN | WasHINgtoN | emergINg eNterPrIse CeNter | foleyHoag.Com

Attorney advertising. Prior results do not guarantee a similar outcome.

© 2009 Foley Hoag LLP. All rights reserved.